WALTHAM, Mass. - Nov. 5, 2020 - Nova Biomedical announces the availability of Nova Primary, a rapid, accurate, easy to use blood glucose reference analyzer. Nova Primary fills the need for a new glucose reference correlation analyzer to replace the YSI 2300 (YSI, Inc., Yellow Springs, OH).

Manufacturers of blood glucose measuring devices and clinical researchers have relied on the YSI 2300 as a reference and correlation analyzer. However, as of July 2021, YSI will no longer support the analyzer, and its discontinuation has left a void. The Nova Primary analyzer fills that need. It will be available in November, 2020 for CE regulated countries and was submitted to the U.S. FDA in November 2020.

Like the YSI 2300, Nova Primary has a single, reusable glucose electrochemical sensor based on glucose oxidase and has a measurement range of 0-1000 mg/dL. It uses a small, 25 microliter whole blood or plasma sample which is internally diluted, and results are available in approximately 2 minutes. Nova Primary's large color touchscreen display and intuitive, icon-based graphical user interface make it very straightforward to use. A single calibrator pack uses RFID data management to monitor the pack expiration date and remaining samples available, eliminating the need for separate reagent bottles and daily monitoring of their levels. The Nova Primary measures 17 in x 11 in x 18 in (44 cm x 28 cm x 46 cm). It has excellent correlation to the YSI glucose analyzer and is traceable to NIST glucose standards.

About Nova Biomedical

Incorporated in 1976 and based in Waltham, MA, Nova Biomedical is a world leader in the development and manufacturing of whole blood, point-of-care and critical care analyzers, as well as instruments for cell culture monitoring in the biotechnology market. Nova uses biosensor technology in products ranging from handheld meters for glucose self- and point-of-care testing to critical care whole blood analyzers designed for stat measurement of over 22 analytes. Nova's BioProfile line has pioneered comprehensive cell culture testing, providing over 20 critical cell culture tests for a broad range of cell culture applications. Nova employs over 1,300 people worldwide and has wholly owned subsidiaries located in Brazil, Canada, Great Britain, France, Spain, Italy, Germany, Switzerland, and Japan. Certified by the International Organization for Standardization, Nova has manufacturing operations located in the U.S. and Brazil.

http://www.novabiomedical.com

Contact
Doug Curley